EUVIMEDEUVIMED entdecken
Open Access

Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital

Sydney Brehany iD, Meryl Colton iD, Cassandra Duarte, Michael Baliton iD, Alec S McCranie iD, Sonia Okuyama iD

JCO Precision Oncology · 2024

DOI: 10.1200/po.23.00699 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Precision Oncology, 2024. Verfasst von Sydney Brehany und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Colorado Cancer Center, Aurora, CO. Hauptthemen laut MEDLINE: Safety-net Providers, Early Detection of Cancer. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Patients with hereditary cancer syndromes (HCS) have a high lifetime risk of developing cancer. Historically underserved populations have lower rates of genetic evaluation. We sought to characterize demographic factors that are associated with undergoing HCS evaluation in an urban safety-net patient population. METHODS All patients who met inclusion criteria for this study from 2016 to 2021 at an urban safety-net hospital were included in this analysis. Inclusion criteria were pathologically confirmed breast, ovarian/fallopian tube, colon, pancreatic, and prostate cancers. Patients also qualified for hereditary breast and ovarian cancers or Lynch syndrome on the basis of National Comprehensive Cancer Network guidelines. Institutional review board approval was obtained. Demographic and oncologic data were collected through retrospective chart review. Univariable and multivariable logistic regression models were constructed. RESULTS Of the 637 patients included, 40% underwent genetic testing. Variables associated with receiving genetic testing on univariable analysis included patients living at the time of data collection, female sex, Latinx ethnicity, Spanish language, family history of cancer, and referral for genetic testing. Patients identifying as Black, having Medicare, having pancreatic or prostate cancer, having stage IV disease, having Eastern Cooperative Oncology Group (ECOG) prognostic score ≥1, having medium or high Charlson comorbidity index, with current or previous cigarette use, and with previous alcohol use were negatively associated with testing. On multivariable modeling, family history of cancer was positively associated with testing. Patients identifying as Black, having colon or prostate cancer, and having ECOG score of 2 had significantly lower association with genetic testing. CONCLUSION Uptake of HCS was lower in patients identifying as Black, those with colon or prostate cancer, and those with an ECOG score of 2. Efforts to increase HCS testing in these patients will be important to advance equitable cancer care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Safety-net ProvidersEarly Detection of CancerHumansFemaleMaleMiddle AgedRetrospective StudiesAgedHospitals, UrbanAdultGenetic TestingNeoplastic Syndromes, Hereditary

Autor:innen und Institutionen

  • University of Colorado Cancer Center, Aurora, CO.
  • University of Colorado School of Medicine, Aurora, CO.
  • Denver Health Hospital Authority, Denver, CO.

ORCID-Profile: Sydney Brehany, Meryl Colton, Michael Baliton, Alec S McCranie, Sonia Okuyama

Zitieren

APA

Brehany, S., Colton, M., Duarte, C., Baliton, M., McCranie, A. S., & Okuyama, S. (2024). Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital. JCO Precision Oncology. https://doi.org/10.1200/po.23.00699

Vancouver

Brehany S, Colton M, Duarte C, Baliton M, McCranie AS, Okuyama S. Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital. JCO Precision Oncology. 2024. doi:10.1200/po.23.00699

BibTeX
@article{Brehany2024,
  author = {Brehany, Sydney and Colton, Meryl and Duarte, Cassandra and Baliton, Michael and McCranie, Alec S and Okuyama, Sonia},
  title = {Hereditary Cancer Screening and Outcomes at an Urban Safety-Net Hospital},
  journal = {JCO Precision Oncology},
  year = {2024},
  doi = {10.1200/po.23.00699}
}
Kostenlos starten →